Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (341-350 of 386) with videos related to

Pageof 39
Sort By:
Nature|December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy responseStephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but AlsoJohn M S Bartlett, Christopher C McConkey, Alison F Munro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysisDuveken B Y Fontein, Caroline Seynaeve, Peyman Hadji, et al.
BMC Cancer|March 29, 2018
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkersCécile Le Page, Kurosh Rahimi, Martin Köbel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL TrialsIris Noordhoek, Erik J Blok, Elma Meershoek-Klein Kranenbarg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patientsH R Ali, E Provenzano, S-J Dawson, et al.
Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
Pageof 39

Showing results (341-350 of 386) with videos related to

Sort By:
Pageof 39
Nature|December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy responseStephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but AlsoJohn M S Bartlett, Christopher C McConkey, Alison F Munro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysisDuveken B Y Fontein, Caroline Seynaeve, Peyman Hadji, et al.
BMC Cancer|March 29, 2018
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkersCécile Le Page, Kurosh Rahimi, Martin Köbel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL TrialsIris Noordhoek, Erik J Blok, Elma Meershoek-Klein Kranenbarg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patientsH R Ali, E Provenzano, S-J Dawson, et al.
Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
Pageof 39